Bayer Proposes $7.25 Billion Nationwide Settlement to Resolve Roundup Cancer Claims as Supreme Court Review Looms

BY EMMANUEL OGBONNA

Agrochemical giant Bayer and attorneys representing thousands of cancer patients unveiled a proposed $7.25 billion settlement Tuesday aimed at resolving a vast share of U.S. lawsuits alleging that the company failed to warn consumers that its widely used weedkiller Roundup could cause cancer.

The agreement, filed in Missouri state court, seeks to bring closure to years of costly and highly publicized litigation centered on claims that exposure to glyphosate—the active ingredient in Roundup—caused non-Hodgkin lymphoma. While Bayer has consistently denied that glyphosate is carcinogenic, the company has faced mounting jury verdicts, legal expenses and investor pressure since acquiring Roundup manufacturer Monsanto in 2018.

The proposed settlement arrives at a pivotal moment. The U.S. Supreme Court is scheduled to hear arguments in April in a separate case in which Bayer contends that federal regulatory approval of Roundup without a cancer warning preempts state-law failure-to-warn claims. That appeal will proceed independently and would not be directly resolved by the new settlement.

Nonetheless, the agreement is structured to mitigate risk for both sides ahead of a potentially far-reaching high court ruling. Plaintiffs who qualify under the settlement would receive compensation even if the Supreme Court sides with Bayer. Conversely, Bayer would cap its exposure to additional large jury verdicts should the justices reject its federal preemption argument.

“Litigation uncertainty has plagued the company for years, and this settlement gives the company a road to closure,” Bayer Chief Executive Bill Anderson said in a statement announcing the proposal.

The settlement was filed in St. Louis Circuit Court, reflecting the significance of Missouri as a focal point for Roundup litigation and as home to Bayer’s North American crop science division. The agreement remains subject to judicial approval.

More than 125,000 plaintiffs have filed claims related to Roundup since 2015, according to court documents. While the majority of cases have been resolved through earlier agreements, dozens proceeded to trial, producing mixed results. Juries have returned 13 verdicts in Bayer’s favor and 11 in favor of plaintiffs. Among the most notable awards was a $2.1 billion verdict issued by a Georgia jury last year. In another case currently under Supreme Court review, a Missouri plaintiff secured a $1.25 million award after alleging that spraying Roundup in a St. Louis community garden led to his diagnosis of non-Hodgkin lymphoma.

Two prior settlement programs resolved approximately 77,000 claims. The newly proposed nationwide framework is designed to address most of the remaining lawsuits, as well as future claims brought by individuals who allege they were exposed to Roundup before the settlement’s announcement. Bayer has reserved the right to withdraw from the agreement if an unspecified number of plaintiffs opt out.

Under the proposal, Bayer would make annual payments into a compensation fund over a period of up to 21 years, totaling as much as $7.25 billion. Individual awards would vary based on several criteria, including the claimant’s level and duration of exposure, age at diagnosis, and the severity and progression of their illness.

According to settlement documents, agricultural, industrial or turf workers who experienced prolonged exposure and were diagnosed before age 60 with an aggressive form of non-Hodgkin lymphoma could receive average payouts of approximately $165,000. Residential users diagnosed between ages 60 and 77 with less aggressive forms of the disease could receive average awards closer to $20,000. Final compensation amounts would depend on individualized assessments within the framework.

Christopher Seeger, an attorney representing current claimants under the proposed settlement, said the structure is intended to ensure that both present and future patients have access to compensation. He emphasized that while financial awards cannot undo a cancer diagnosis, the agreement seeks to provide meaningful redress and reduce prolonged litigation.

The legal battle over Roundup has centered on conflicting scientific assessments of glyphosate. Some studies have suggested a potential link between glyphosate exposure and cancer, while the U.S. Environmental Protection Agency has maintained that glyphosate is not likely to be carcinogenic to humans when used in accordance with label instructions. Roundup’s federally approved labeling does not include a cancer warning.

Bayer argues that because the EPA has approved Roundup’s labeling under federal pesticide laws, states cannot impose additional warning requirements through tort litigation. The company’s appeal before the Supreme Court asserts that such claims are preempted by federal law. A ruling in Bayer’s favor could sharply limit similar lawsuits nationwide, while an adverse decision could reinforce the authority of state courts to entertain failure-to-warn claims.

The case has drawn political attention as well. The administration of Donald Trump has submitted arguments supporting Bayer’s position before the Supreme Court, reversing the stance taken under former President Joe Biden. The shift has generated debate among some public health advocates and supporters of regulatory reform who oppose broader legal protections for pesticide manufacturers.

Beyond the courtroom, Bayer has sought legislative remedies at the state level. The company has lobbied for laws that would shield pesticide manufacturers from state-based failure-to-warn claims if their products comply with federal labeling requirements. North Dakota became the first state to enact such a statute last April, followed by Georgia in May.

In response to litigation pressures, Bayer previously reformulated Roundup products sold in the U.S. residential lawn and garden market to remove glyphosate, though the compound remains in agricultural formulations. Glyphosate is commonly paired with genetically engineered seeds designed to tolerate the herbicide, allowing farmers to control weeds efficiently while minimizing soil disruption through reduced tilling.

The proposed settlement represents one of the largest mass tort resolutions in recent years and underscores the enduring legal and financial consequences of Bayer’s acquisition of Monsanto. Whether it ultimately achieves the “closure” the company seeks will depend not only on court approval and claimant participation but also on the forthcoming decision from the nation’s highest court, which could reshape the legal landscape for pesticide manufacturers across the United States.